The Epigenetics Revolution is upon us…

EpiCongress London is a premier networking, interactive and solution-led conference that addresses how to understand the basic mechanisms behind genome regulation and chromatin function. 

This is a meeting where attendees discover industry-defining information, and expand their network to achieve to ensure effective application of epigenetic science to ensure the success of current and future drug candidates.

Epigenetics is a field growing in importance when it comes to understanding a cell’s transformation to cancer so understanding  the epigenetic mechanisms involved will have a significant impact on cancer prevention, diagnosis and therapy. 

EpiCongress London will ensure you develop a cutting edge understanding for making clinically relevant predictions and tap into the potential of epigenetics to generate new cancer drugs:

  • Learn about genome regulation to explore the therapeutic opportunities in altered epigenomic states
  • Explore the biology and pharmacological properties behind selected HMT and demethylases compounds 
  • Get to grips with heterogeneity in neuropsychiatric disorders to see  how it can impact your therapeutic strategies
  • Get an insight into unpublished data from the industry’s exciting EZH2 programs
  • Understand the chemistry behind LSD1 histone methyltransferases and demethylases to develop potent and specific small molecule inhibitors
  • Improve your target validation by identifying which inhibitors are ticking all the boxes for pharma
  • Choose the most effective biomarker strategies for your program and discuss what clinical biomarkers will look like for novel epigenetic drugs
  • Discover how companies are currently selecting their PK/PD endpoints for early clinical trials
  • Learn from those who have achieved successful patient selection so far in phase I & II trials 

 

2013-Featured Speakers

  • Andrea Cochran Senior Scientist Genentech

  • Bob CopelandExecutive VP & CSO Epizyme

  • Peter Staller Director of Oncology Research EpiTherapeutics

  • Dominique Verhelle Director of Epigenetics Pfizer

About Us